<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<GBSeq>

    <GBSeq_locus>OF267345</GBSeq_locus>
    <GBSeq_length>681</GBSeq_length>
    <GBSeq_strandedness>double</GBSeq_strandedness>
    <GBSeq_moltype>DNA</GBSeq_moltype>
    <GBSeq_topology>linear</GBSeq_topology>
    <GBSeq_division>PAT</GBSeq_division>
    <GBSeq_update-date>16-DEC-2021</GBSeq_update-date>
    <GBSeq_create-date>16-DEC-2021</GBSeq_create-date>
    <GBSeq_definition>KR 1020210043647-A/7: HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF</GBSeq_definition>
    <GBSeq_primary-accession>OF267345</GBSeq_primary-accession>
    <GBSeq_accession-version>OF267345.1</GBSeq_accession-version>
    <GBSeq_other-seqids>
      <GBSeqid>dbj|OF267345.1|</GBSeqid>
      <GBSeqid>pat|KR|1020210043647|7</GBSeqid>
      <GBSeqid>gi|2166303482</GBSeqid>
    </GBSeq_other-seqids>
    <GBSeq_keywords>
      <GBKeyword>KR 1020210043647-A/7</GBKeyword>
    </GBSeq_keywords>
    <GBSeq_source>Hepatitis B virus</GBSeq_source>
    <GBSeq_organism>Hepatitis B virus</GBSeq_organism>
    <GBSeq_taxonomy>Viruses; Riboviria; Pararnavirae; Artverviricota; Revtraviricetes; Blubervirales; Hepadnaviridae; Orthohepadnavirus</GBSeq_taxonomy>
    <GBSeq_references>
      <GBReference>
        <GBReference_reference>1</GBReference_reference>
        <GBReference_position>1..681</GBReference_position>
        <GBReference_authors>
          <GBAuthor>Jadhav,V.R.</GBAuthor>
          <GBAuthor>Maier,M.A.</GBAuthor>
          <GBAuthor>Milstein,S.</GBAuthor>
          <GBAuthor>Schlegel,M.K.</GBAuthor>
        </GBReference_authors>
        <GBReference_title>HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF</GBReference_title>
        <GBReference_journal>KR1020210043647-A 7 21-APR-2021 Alnylam Pharmaceuticals, Inc</GBReference_journal>
      </GBReference>
    </GBSeq_references>
    <GBSeq_comment>KN KR 1020217007642-A/7~AN KR 1020217007642~AD 2021-03-12~PN KR 1020210043647~PD 2021-04-21~AT HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS~AT OF USE THEREOF~AI Jadhav, Vasant R.|Maier, Martin A.|Milstein, Stuart|Schlegel,~AI Mark K.~AA Alnylam Pharmaceuticals, Inc.~PR US 62/718,314=2018-08-13~OS Hepatitis B virus~TY DNA~CC HBV, genotype C~FH Key Location/Qualifiers.</GBSeq_comment>
    <GBSeq_feature-table>
      <GBFeature>
        <GBFeature_key>source</GBFeature_key>
        <GBFeature_location>1..681</GBFeature_location>
        <GBFeature_intervals>
          <GBInterval>
            <GBInterval_from>1</GBInterval_from>
            <GBInterval_to>681</GBInterval_to>
            <GBInterval_accession>OF267345.1</GBInterval_accession>
          </GBInterval>
        </GBFeature_intervals>
        <GBFeature_quals>
          <GBQualifier>
            <GBQualifier_name>organism</GBQualifier_name>
            <GBQualifier_value>Hepatitis B virus</GBQualifier_value>
          </GBQualifier>
          <GBQualifier>
            <GBQualifier_name>mol_type</GBQualifier_name>
            <GBQualifier_value>unassigned DNA</GBQualifier_value>
          </GBQualifier>
          <GBQualifier>
            <GBQualifier_name>db_xref</GBQualifier_name>
            <GBQualifier_value>taxon:10407</GBQualifier_value>
          </GBQualifier>
        </GBFeature_quals>
      </GBFeature>
    </GBSeq_feature-table>
    <GBSeq_sequence>atggagaacacaacatcaggattcctaggacccctgctcgtgttacaggcggggtttttcttgttgacaagaatcctcacaataccacagagtctagactcgtggtggacttctctcaattttctagggggagcacccacgtgtcctggccaaaattcgcagtccccaacctccaatcactcaccaacctcttgtcctccaatttgtcctggctatcgctggatgtgtctgcggcgttttatcatattcctcttcatcctgctgctatgcctcatcttcttgttggttcttctggactaccaaggtatgttgcccgtttgtcctctacttccaggaacatcaactaccagcacgggaccatgcaagacctgcacgattcctgctcaaggaacctctatgtttccctcttgttgctgtacaaaaccttcggacggaaactgcacttgtattcccatcccatcatcctgggctttcgcaagattcctatgggagtgggcctcagtccgtttctcctggctcagtttactagtgccatttgttcagtggttcgtagggctttcccccactgtttggctttcagttatatggatgatgtggtattgggggccaagtctgtacaacatcttgagtccctttttacctctattaccaattttcttttgtctttgggtatacatttga</GBSeq_sequence>
  </GBSeq>
